Penetration of Moxifloxacin Into Liver Tissue of Patients Undergoing Liver Resection.

• Status: Completed
• Trial end date: 2010-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the study is to provide data on the pharmacokinetics (PK) of moxifloxacin (MXF) in serum and liver tissue of patients undergoing liver resection due to primary or secondary tumor of the liver.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Saarland
• Collaborator: Bayer
• Treatments: Fluoroquinolones; Moxifloxacin; Norgestimate, ethinyl estradiol drug combination

Criteria

Inclusion Criteria:

• age 18-80 years old

• elective liver resection of liver tumor

• in females: pregnancy test negative

• Subjects willing and able to give fully informed written consent

Exclusion Criteria:

• subjects with contra-indications to Moxifloxacin

• subjects under therapy with Moxifloxacin within 2 weeks before recruitment